Clinical trials: Solid Malignant Tumor
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Malignant Solid Neoplasm
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or…
- Trial name
- NCT04871542
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 849 sites in United States, Chile and 3 more
- Volunteers
- 2,062 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells.
- Trial name
- NCT00389805
- Testing
- bortezomib, pemetrexed disodium, gene expression analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Solid Tumor, Adult
Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit
The aim of CPV 2.0 study is to evaluate a process of digital prevalidation of outpatients chemotherapy thanks to a numeric application.
- Trial name
- CPV2-0 (NCT03977766)
- Testing
- Chemotherapy prevalidation
- Volunteers
- 150 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Solid Tumor, Trop2
68Ga-MY6349 PET/CT in Solid Tumors
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
- Conditions
- Solid Tumor, Trop2, PET/CT
- Trial name
- NCT07046702
- Testing
- 68Ga-MY6349
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NKTR-214 (NCT02869295)
- Testing
- NKTR-214
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Nektar Therapeutics
Locally Advanced or Metastatic Solid Tumors
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD…
- Trial name
- NCT05830539
- Testing
- IN10018+PLD, IN10018+PLD+Toripalimab
- Where
- 7 sites in China
- Volunteers
- 68 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Breast Cancer, Neoplasm Metastasis
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
- Trial name
- NCT01118975
- Testing
- Vorinostat, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant…
- Trial name
- NCT05775666
- Testing
- UCLM802 Cell Injection
- Volunteers
- 87 people
- Sponsor
- Peking University
Solid Tumors
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in…
- Trial name
- NCT04589845
- Testing
- Entrectinib, Alectinib, Atezolizumab
- Where
- 112 sites in United States, Australia and 21 more
- Volunteers
- 920 people
- Sponsor
- Hoffmann-La Roche
Cutaneous Tumor, Malignant Solid Tumor
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
- Trial name
- NCT05539157
- Testing
- JCXH-211
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Immorna Biotherapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
BMS-599626 in Treating Patients With Metastatic Solid Tumors
RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with…
- Trial name
- NCT00093730
- Testing
- BMS-59926
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
RATIONALE: Biological therapies, such as anakinra, may interfere with the growth of the tumor cells and slow the growth of metastatic tumors that express the interleukin-1 gene.
- Trial name
- NCT00072111
- Testing
- anakinra
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Childhood Cancer, ALL, Childhood
Retun-to-school Adaptation Program for Children With Cancer
The aim of this action research is to: Stage 1: Conduct an in-depth investigation into the adaptation challenges faced by children aged 8-17 who are being treated for cancer during their return to school, from both the children's…
- Conditions
- Childhood Cancer, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- web-based (NCT06389357)
- Testing
- training and counselling, Interview
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
This clinical trial tests how well aromatherapy essential oils work to manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting.
- Trial name
- NCT07126301
- Testing
- Aromatherapy and Essential Oils, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumor, Metastatic Solid Tumor
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
- Trial name
- PROBE (NCT04986865)
- Testing
- ATG-101
- Where
- 8 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- Antengene Biologics Limited
Advanced Solid Malignant Tumors
Open Label Study of DS-5573a
This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.
- Trial name
- NCT02192567
- Testing
- DS-5573a
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.